ClinicalTrials.gg
Not yet recruitingNCT07564193Updated May 11, 2026

The Coach Mpilo Study: Evaluation of a Peer-led Intervention to Promote Engagement in HIV Care for Men Living With HIV

An interventional study of Coach Mpilo in HIV, sponsored by University of Cape Town. Not yet recruiting at 1 site in South Africa. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-11.

Sponsored by University of Cape Town · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
800
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Developed in South Africa using extensive input from community members and healthcare professionals, Coach Mpilo is a peer support intervention that was designed to improve health outcomes for men living with HIV. Coach Mpilo engages men living with HIV as coaches who provide support to their peers and help them address psychosocial barriers in accessing and staying in HIV care. The peers employed by Coach Mpilo provide individualized assistance to men who are struggling with medication adherence and clinic visits, focusing on specific barriers ranging from knowledge about the benefits of HIV treatment, stigma, mental health, and social isolation.

Through a randomised control trial, this project will (1) determine the impact of the Coach Mpilo intervention on retention in HIV care, viral suppression, HIV treatment adherence, mental health, HIV stigma, and economic status; (2) identify populations of men who may not benefit from the intervention and require alternative support; and (3) assess the intervention's cost-effectiveness.

Read the detailed description

Study setting The study will be conducted in KwaZulu-Natal (KZN), the province in South Africa with the highest adult HIV prevalence: 16%-24% (model estimates), 22% (survey estimates). The study will be conducted in about 13 primary healthcare facilities based in the eThekwini District.

Aim 1: Determine the effects of Coach Mpilo on retention in care among men living with HIV In partnership with the Department of Health in KwaZulu-Natal Province, eThekwini Municipality, The Health Systems Trust (HST) and Matchboxology (a South African organisation that designs health and social programs) a randomised controlled trial (RCT) will be conducted with men living with HIV who have dropped out of HIV care (i.e., having missed a clinic appointment by >28 days).

Recruitment: Study staff will be trained by HST as Linkage Officers. As Linkage Officers, they will contact men who have missed clinic appointments via telephone, encourage return to care, and ask to meet privately at local venues. At the in-person meeting the Linkage Officers will invite eligible participants to enrol in the study.

Consenting process: Written informed consent will be obtained.

Data collection Baseline survey: Study staff will administer a baseline questionnaire to obtain information on, among other things, participants' demographic characteristics, socio-economic status, health behaviour, future outlook, internalized stigma and mental health.

Follow-up survey: Study staff will contact participants at six months and administer an in-person follow-up survey; many of the questions administered at baseline will be assessed again.

Clinic records: Participants' health outcome data will be obtained from electronic clinic data via TIER.Net (South Africa's national electronic HIV/TB monitoring system), to assess individual- and facility-level outcomes related to HIV. Where necessary physical clinic files will be reviewed for confirmation. In addition, participants' data on laboratory tests relevant for HIV care (including viral load tests) will be requested from the National Health Laboratory Services (NHLS).

Coach Log Book: To collect data on the engagement between coaches and their clients, the coaches will maintain a log book of the dates, duration and mode (e.g., in-person, telephone call, WhatsApp messages) of contact with clients.

Randomization: Following the baseline survey, participants will be randomized (1:1) to a control group that receives the SOC and an intervention group that receives SOC plus the Coach Mpilo intervention.

Analyses: Primary analysis will be intention-to-treat using a logistic regression model that includes clinic fixed effects and month of enrollment, and controls for baseline participant characteristics that are significantly different between study groups. Similar analyses will be conducted for each secondary outcome.

Sample size and power calculations: With a sample size of 786 participants and 50% retention in care at 12 months, the study has 80% power to detect a difference of 10 percentage points between study groups. As a result, the study will aim to recruit about 800 participants in the Aim 1 trial.

Aim 2: Identify the populations of men who are not reached by and do not respond to Coach Mpilo In the intervention group, intervention uptake and amount of engagement participants have with a coach will be measured. Primary quantitative analysis will assess the determinants of uptake within the intervention group to advance the limited evidence on sub-groups that are typically missed by peer-led interventions and therefore require different types of support. Qualitative interviews will also be conducted to better understand program uptake and engagement with a coach.

Participants: Aim 2 will be conducted with data collected from coaches and from Aim 1 trial participants.

Follow-up procedures and data collection: In-depth interviews (IDIs) with participants in the intervention arm who decline a coach. The study will conduct about 15 IDIs with 1) men who decline the support of a coach to understand reasons they did not engage with a coach; 2) about 15 IDIs with men who, after initial engagement, decline the support of a coach, this will be in order to understand reasons they chose to end engagements with a coach; 3) about 15 IDIs with participants who receive support from a coach to understand engagement with coaches and elicit insights on reasons why the intervention may have worked for some participants but not others. IDIs will be conducted at about 6 months, when engagement with a coach will have ended.

IDIs with all coaches (about N=7) involved in the study will be conducted to gain insights on their engagement with participants.

Analyses: Primary quantitative analysis: Among Aim 1 intervention group participants analysis will evaluate factors associated with declining the offer of a coach using logistic regression, controlling for potential covariates. Qualitative data analysis: Data analysis will be iterative, and include both deductive and inductive approaches to thematic analysis.

Aim 3: Assess the cost-effectiveness of the Coach Mpilo program To inform strategic policy decisions about the scale-up of Coach Mpilo, and how it compares in cost and cost-effectiveness against current standard of care treatment, as well as other HIV interventions, we will conduct an economic evaluation. Data collection includes: cost-related data and resource utilization data to construct cost estimates for both arms. These data will be combined with retention in care data from Aim 1 to determine average costs per client retained in care and incremental cost per additional person retained. As part of the analysis, a sub-analysis will be conducted to adjust the cost estimates to reflect implementation in a routine care setting, excluding research-related expenses such as start-up and study-specific costs. This will provide more realistic national-level scale-up cost estimates for Coach Mpilo. Epidemiological modeling based on effectiveness estimates from Aim 1, will use the Thembisa model to estimate several long-term health outcomes, including life years saved and HIV infections averted due to onward transmission. These long-term health outcomes will form the basis to estimate the cost-effectiveness analysis of Coach Mpilo. To compare Coach Mpilo to other HIV prevention and treatment options in South Africa with the broader aim of informing strategic policy decisions, study estimates will be incorporated into the South Africa HIV Investment Case, a prominent initiative that assesses the relative cost-effectiveness of different HIV interventions and aims to inform government of the optimal mix of interventions that also accounts for allocative efficiency.

Analyses

The analyses will be conducted in three phases:

Cost analysis: a multiprong approach will be used that incorporates top-down and bottom-up costing methodologies to construct a cost for both standard of care and Coach Mpilo arms.

Cost-effectiveness analysis: both intermediate and long-term cost effectiveness analysis (using an HIV transmission model) will be conducted, comparing Coach Mpilo to standard of care.

Integration into the HIV Investment Case: the cost-effectiveness of Coach Mpilo to other HIV prevention and treatment options in South Africa will be compared to inform strategic policy decisions for the South African government.

Aim 4: Assess the acceptability, feasibility and fidelity of the Coach Mpilo program To inform intervention refinements and policy decisions on the scale-up of Coach Mpilo and peer-led interventions more generally, quantitative and qualitative assessment of implementation outcomes will be conducted alongside effectiveness and cost-effectiveness of the intervention. Implementation outcomes will be viewed as important for evaluation of complex health interventions in research and practice, providing indications into the implementation process as preconditions for attaining intended intervention engagement and health outcomes.

Sekhon's 2017 Theoretical Framework for Acceptability (TFA) will be used to assess the feasibility and acceptability of the intervention, informing interpretation of effectiveness overall (Aim 1), for sub-groups (Aim 2), and cost-effectiveness (Aim 3) by describing how acceptable the intervention is and how feasible the intervention is to deliver, from different stakeholder perspectives, and by describing the fidelity of the intervention.

The following data will be collected: i) primary quantitative survey data at baseline and six month follow-up (through Aim 1 survey instruments); ii) primary qualitative data from intervention arm participants that decline a coach, participants who are supported by a coach at six-month follow up, and coaches immediately after the intervention stops being implemented (through Aim 2 IDI instruments); iii) routine administrative data during intervention preparation and implementation.

Quantitative: At baseline, participants' affective attitude and values alignment will be assessed to understand prospective acceptability. In the follow up survey with intervention arm participants, the Acceptability of Intervention Measure (AIM)19, and the Client Satisfaction Questionnaire (CSQ-8) will be asked.

Qualitative: Follow-up in-depth-interviews described in Aim 2 include topics which answer our implementation research questions, focusing on retrospective acceptability

Coach log: an existing routine administrative data collection tool has been adapted to focus on implementation choices, their determinants, and coach-participant relationship quality.

Coach-to-Coach WhatsApp Group: the implementing partner routinely establishes a WhatsApp group used by Coaches and the Squad Manager (i.e. not including any clients/participants). Data from this group will include challenges Coaches are facing and solutions suggested by other coaches.

Monthly and quarterly implementation reports and follow-up discussions: these reports will be developed by Matchboxology, providing both quantitative data on reach and their own observations on fidelity, reach, mechanisms of change and implementation strategies and determinants.

Analysis: Quantitative analysis. Among Aim 1 intervention group participants, descriptive analysis of data from the AIM and CSQ-8 scales and linear regression analysis will be conducted to assess what factors at baseline were associated with these scales. Qualitative data analysis. Ongoing saturation analyses will be conducted, based on iterative coding during data collection. Data analysis will be iterative, and include both deductive and inductive approaches to thematic analysis.

02

Conditions studied

  • HIV

Keywords

  • HIV
  • antiretroviral therapy (ART)
  • re-engagement in HIV care
  • linkage to care
  • peer-support
  • Coach Mpilo
  • men living with HIV
  • South Africa
  • ARV
03

In context

Lead sponsor

University of Cape Town is the lead sponsor of 116 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male (cisgender or transgender);
  • aged ≥18 years;
  • previously receiving care at the study clinic;
  • missed their most recent ART (antiretroviral therapy) clinic appointment by >28 days;
  • not planning to relocate to another region within the next 12 months;
  • able and willing to provide ;
  • not currently taking ART

Exclusion criteria

Exclusion Criteria:

  • not meeting inclusion criteria
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
800 participants (estimated)

Study arms

  • No intervention
    Control group

    Standard of care (SOC) in our study is a once-off telephonic contact by a Study Linkage Officer to encourage the participant to return to HIV care. The Linkage Officer is trained to conduct the call in line with the South African National Guidelines on tracing and recall which involved making telephonic contact with an individual who has missed their HIV clinic appointment by 7 days. The National Guidelines for tracing also include a potential home visit if the telephone call is unsuccessful. Given our study sample is limited to men who have missed HIV clinic appointments by more than 28 days, all participants should already have received the standard tracing services provided by the health facility. In the study we conduct the tracing telephone call again to make sure all participants have received this service. No other intervention is provided.

  • Experimental
    Coach Mpilo group

    The experimental group receives the standard of care for the control group (see control group description) and the Coach Mpilo intervention. Coach Mpilo employs 'coaches' (a term found to resonate with men and the concept of 'getting back in the game') to work 1-on-1 with men living with HIV ('players') and tailor support for each man to help him re-engage and stay in care. Coaches provide support for a period of up to six months, during which they engage with clients about once every week, with greater contact as needed based on the complexity of challenges faced. Coach Mpilo provides one-on-one, in-person support tailored to the individual needs of men living with HIV. As such, it may address the complex and varying psychosocial barriers to HIV care that traditional clinic-based interventions typically overlook. Coach Mpilo employs men living openly with HIV as coaches. This leverages the coaches' personal experiences to create a safe and supportive environment for clients.

    Behavioral: Coach Mpilo

Interventions

  • BehavioralCoach Mpilo

    The experimental group receives the standard of care for the control group (see control group description) and the Coach Mpilo intervention. Coach Mpilo employs 'coaches' (a term found to resonate with men and the concept of 'getting back in the game') to work 1-on-1 with men living with HIV ('players') and tailor support for each man to help him re-engage and stay in care. Coaches provide support for a period of up to six months, during which they engage with clients about once every week, with greater contact as needed based on the complexity of challenges faced. Coach Mpilo provides one-on-one, in-person support tailored to the individual needs of men living with HIV. As such, it may address the complex and varying psychosocial barriers to HIV care that traditional clinic-based interventions typically overlook. Coach Mpilo employs men living openly with HIV as coaches. This leverages the coaches' personal experiences to create a safe and supportive environment for clients.

06

What researchers measure

Primary outcomes

  1. Retention in HIV care

    Indicates whether a participant attended a follow-up clinic visit on or before 12 months after study enrolment and obtained adequate supply of antiretroviral therapy (ART) medication to have medication available at 12 months

    Time frame: 12 months post study enrolment

Secondary outcomes

  1. ART clinic visit by 6 months

    Indicates whether an participant attends an antiretroviral therapy (ART) related clinic visit within 6 months of study enrolment

    Time frame: 6 months post study enrolment

  2. Retention in HIV care at 6 months

    Indicates whether a participant attended a follow-up clinic visit on or before 6 months after study enrolment and obtained adequate supply of antiretroviral therapy (ART) medication to have medication available at 6 month

    Time frame: 6 months post study enrolment

  3. Viral load test completed at 6 months

    Indicates whether a participant completed an HIV viral load test within 6 months of study enrolment

    Time frame: 6 months post study enrolment

  4. Viral suppression at 6 months

    Indicates whether a participant had a viral load test conducted between 3-9 months after study enrolment and the test result was an HIV viral load \<50 copies/ml

    Time frame: 3 to 9 months post study enrolment

  5. Viral suppression at 12 months

    Indicates whether a participant had a viral load test conducted between 9-15 months after study enrolment and the test result was an HIV viral load \<50 copies/ml

    Time frame: 9 to 15 months post study enrolment

  6. HIV status disclosure to sexual partners

    Indicates whether a participant disclosed their HIV status to all sexual partners reported in the 6 months prior to the 6 month follow-up survey

    Time frame: 6 months post study enrolment

  7. PHQ-9 scale

    The participant's score on the PHQ-9 scale, which assessed symptoms of depression. The Patient Health Questionnaire-9 (PHQ-9) score ranges from 0 to 27, with higher scores indicating greater depression severity.

    Time frame: 6 months post study enrolment

  8. Mild to severe symptoms of mental depression

    Binary indicator of PHQ-9 score ≥5

    Time frame: 6 months post study enrolment

  9. Moderate to severe symptoms of mental depression

    Binary indicator of PHQ-9 score ≥10

    Time frame: 6 months post study enrolment

  10. GAD-7 scale

    The participant's score on the GAD-7 scale, which assesses symptoms of anxiety. The GAD-7 (Generalized Anxiety Disorder-7) scale ranges from 0 to 21, with higher scores indicating greater anxiety severity.

    Time frame: 6 months post study enrolment

  11. Mild to severe symptoms of anxiety

    Binary indicator of GAD-7 score ≥5

    Time frame: 6 months post study enrolment

  12. Moderate to severe symptoms of anxiety

    Binary indicator of GAD-7 score ≥10

    Time frame: 6 months post study enrolment

  13. Internalised stigma

    Participant's score on the internalised stigma scale. The score ranges from 0 to 15, with higher scores representing greater internalised stigma.

    Time frame: 6 months post study enrolment

  14. Employment

    Indicates whether a participant did any kind of work for pay or profit in the past 7 days

    Time frame: 6 months post study enrolment

07

Study locations

1 site
  • Multisite study with several health care facilities
    Durban, KwaZulu-Natal, South Africa
08

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Survey data and in-depth interview data; excluding personal identifying information

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code

Time frame: Data will be made publicly available through DataFirst within 12 months from the data collection for the study

Access criteria: Data will be available through DataFirst. Individuals who successfully register with DataFirst will have access. There are no specific exclusion criteria

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07564193
Collaborators
University of Pennsylvania, University of Witwatersrand, South Africa
Responsible party
Brendan Maughan-Brown (Chief Research Officer, University of Cape Town) — Principal investigator
First posted
May 4, 2026
Start date
May 11, 2026 (estimated)
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
May 11, 2026

Study contacts

Brendan G Maughan-Brown, PhD
Contact
brendan.maughan-brown@uct.ac.za
+27216505696
Harsha Thirumurthy, PhD
Contact
hthirumu@pennmedicine.upenn.edu
Brendan G Maughan-Brown, PhD
principal investigator · University of Cape Town
Harsha Thirumurthy, PhD
principal investigator · University of Pennsylvania

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion